Adaptive biotechnologies stock.

SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.DOI: 10.1200/JCO.21.00377 Journal of Clinical Oncology - published online before print June 16, 2021 . PMID: 34133196Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Aug 2, 2023 · Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The estimated net worth of Chad M. Cohen is at least $134,139.07 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $134,139 as of November 28th. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net …Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.28) $ (0.43) $ (1.40) $ (1.48) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 143,054,722 141,228,918 142,515,917 140,354,915SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the strengths of Adaptive’s next-generation ...

2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ...

Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ...

Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetPhone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …ADPT - Adaptive Biotechnologies Corp Stock quote - CNNMoney.com Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / …Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...Complete Adaptive Biotechnologies Corp. stock information by Barron's. View real-time ADPT stock price and news, along with industry-best analysis. Adaptive Biotechnologies (NASDAQ:ADPT shareholders incur further losses as stock declines 17% this week, taking three-year losses to 76%

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...

Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...On June 2, David Westenberg at Piper Sandler initiated coverage on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock with a Neutral rating and a target price of $7.50.

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 …Adaptive Biotechnologies Corp. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:51 p.m. EST Delayed quote $ 4.2000 -0.17 -3.89% After Hours Volume: 4.47K Advanced... Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Historical daily share price chart and data for Adaptive Biotechnologies since 2019 adjusted for splits and dividends. The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37.. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on January 22, 2021.; The Adaptive …Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...

May 12, 2023 · Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …Jun 2, 2023 · Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ... The whole human proteome may be free to browse thanks to DeepMind, but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. Glyphic Biotechnologies accelerates the critical but sl...Real time Adaptive Biotechnologies (ADPT) stock price quote, stock graph, news & analysis.Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT.Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ...SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Dec 4, 2023 · The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. Instagram:https://instagram. best performing fidelity fundsconsolidated communications holdings incstock indicator appbest place to retire in nevada 2023 Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% … ezflyrefinery stocks Adaptive Biotechnologies (ADPT) is a biotech company that develops an immune medicine platform for various diseases. The stock has a consensus rating of …The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts. teum stock Biotechnology is a rapidly evolving field that combines biology and technology to develop innovative solutions for various industries. Pursuing a B Tech in Biotechnology can open up exciting career opportunities in research, healthcare, agr...According to the Biotechnology Industry Organization, there are more than 250 biotechnology products available, including medicines, vaccines, fertilizers, pest-resistant crops, bio-fuels and bio-defense products.